It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BCRX’s FA Score shows that 1 FA rating(s) are green whileVCYT’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BCRX’s TA Score shows that 6 TA indicator(s) are bullish while VCYT’s TA Score has 5 bullish TA indicator(s).
BCRX (@Pharmaceuticals: Generic) experienced а -0.81% price change this week, while VCYT (@Medical Specialties) price change was +27.99% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +8.75%. For the same industry, the average monthly price growth was +16.39%, and the average quarterly price growth was +81.07%.
The average weekly price growth across all stocks in the @Medical Specialties industry was +2.13%. For the same industry, the average monthly price growth was +3.68%, and the average quarterly price growth was -0.14%.
BCRX is expected to report earnings on Oct 29, 2025.
VCYT is expected to report earnings on Nov 11, 2025.
A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
@Medical Specialties (+2.13% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
BCRX | VCYT | BCRX / VCYT | |
Capitalization | 1.79B | 2.41B | 74% |
EBITDA | 47.6M | 53.8M | 88% |
Gain YTD | 13.431 | -22.525 | -60% |
P/E Ratio | N/A | 90.24 | - |
Revenue | 503M | 463M | 109% |
Total Cash | 295M | 287M | 103% |
Total Debt | 795M | 50.5M | 1,574% |
BCRX | VCYT | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 55 | 4 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 32 Undervalued | 73 Overvalued | |
PROFIT vs RISK RATING 1..100 | 80 | 100 | |
SMR RATING 1..100 | 100 | 88 | |
PRICE GROWTH RATING 1..100 | 62 | 60 | |
P/E GROWTH RATING 1..100 | 100 | 75 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BCRX's Valuation (32) in the Biotechnology industry is somewhat better than the same rating for VCYT (73). This means that BCRX’s stock grew somewhat faster than VCYT’s over the last 12 months.
BCRX's Profit vs Risk Rating (80) in the Biotechnology industry is in the same range as VCYT (100). This means that BCRX’s stock grew similarly to VCYT’s over the last 12 months.
VCYT's SMR Rating (88) in the Biotechnology industry is in the same range as BCRX (100). This means that VCYT’s stock grew similarly to BCRX’s over the last 12 months.
VCYT's Price Growth Rating (60) in the Biotechnology industry is in the same range as BCRX (62). This means that VCYT’s stock grew similarly to BCRX’s over the last 12 months.
VCYT's P/E Growth Rating (75) in the Biotechnology industry is in the same range as BCRX (100). This means that VCYT’s stock grew similarly to BCRX’s over the last 12 months.
BCRX | VCYT | |
---|---|---|
RSI ODDS (%) | 2 days ago87% | 2 days ago86% |
Stochastic ODDS (%) | 2 days ago80% | 2 days ago90% |
Momentum ODDS (%) | 2 days ago73% | 2 days ago84% |
MACD ODDS (%) | 2 days ago82% | 2 days ago83% |
TrendWeek ODDS (%) | 2 days ago80% | 2 days ago76% |
TrendMonth ODDS (%) | 2 days ago82% | 2 days ago79% |
Advances ODDS (%) | 2 days ago79% | 2 days ago72% |
Declines ODDS (%) | 4 days ago79% | 15 days ago82% |
BollingerBands ODDS (%) | 2 days ago78% | 2 days ago90% |
Aroon ODDS (%) | 2 days ago81% | 2 days ago80% |
A.I.dvisor indicates that over the last year, BCRX has been loosely correlated with VCYT. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if BCRX jumps, then VCYT could also see price increases.
Ticker / NAME | Correlation To BCRX | 1D Price Change % | ||
---|---|---|---|---|
BCRX | 100% | +2.16% | ||
VCYT - BCRX | 46% Loosely correlated | +6.64% | ||
CRNX - BCRX | 42% Loosely correlated | +5.65% | ||
HOWL - BCRX | 39% Loosely correlated | +12.50% | ||
ROIV - BCRX | 38% Loosely correlated | +3.37% | ||
BEAM - BCRX | 38% Loosely correlated | +3.91% | ||
More |